Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine ([18F]CPFPX): A potent and selective A1-adenosine receptor antagonist for in vivo imaging

Journal of Medicinal Chemistry

Volumn 45, Issue 23, 2002, Pages 5150-5156

  Holschbach, Marcus H ^a   Olsson, Ray A ^a,b   Bier, Dirk ^a   Wutz, Walter ^a   Sihver, Wiebke ^a   Schüller, Manfred ^a   Palm, Bettina ^a   Coenen, Heinz H ^a  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,7 DIMETHYL 1 PROPARGYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYL 3 (3 FLUOROPROPYL) 1 PROPYLXANTHINE F 18; ADENOSINE A1 RECEPTOR ANTAGONIST; DRUG CARRIER; DRUG METABOLITE; FLUORINE 18; N 0840; N6 CYCLOPENTYL 9 METHYLADENINE; POLYETHER; POTASSIUM CARBONATE; RADIOLIGAND; TOLUENESULFONIC ACID DERIVATIVE; TRACER; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CHROMATOGRAPHY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; FLUORINATION; IMAGING; IN VIVO STUDY; MOUSE; NONHUMAN; POLARIZATION; RADIOACTIVITY; RADIOCHEMISTRY; RAT; RECEPTOR BLOCKING;

ANIMALS; BLOOD PROTEINS; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE; CRICETINAE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; ISOTOPE LABELING; LIGANDS; MICE; PROTEIN BINDING; RATS; RECEPTORS, PURINERGIC P1; SWINE; TISSUE DISTRIBUTION; XANTHINES;

EID: 0037038328     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020905i     Document Type: Article

References (29)

1. Fredholm, B. B.; Abbracchio, M. P.; Burnstock, G.; Daly, J. W.; Harden, T. K.; Jacobson, K. A.; Leff, P.; Williams M. Nomenclature and classification of purinoceptors. Pharmacol. Rev. 1994, 46, 143-156.
2. 1 receptors and 5′-nucleotidase in the brain of some commonly used experimental animals. Neuroscience 1987, 22, 813-826.
3. 1 receptor binding in the post-ischaemic rat brain. NeuroReport 1994, 5, 1453-1456.
4. Belardinelli, L.; Shryock, J. C.; Song, Y.; Wang, D.; Srinavas, M. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J. 1995, 9, 359-365.
5. Di Marco, J. P.; Sellers, T. D.; Lerman, B. B.; Greenberg, M. L.; Berne, R. M.; Belardinelli, L. Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. J. Am. Coll. Cardiol. 1985, 6, 417-425.
6. + channels in cerebral ischemic preconditioning. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 4666-4670.
7. Nakano, A.; Cohen, M. V.; Downey, J. M. Ischemic preconditioning. From basic mechanisms to clinical applications. Pharmacol. Ther. 2000, 86, 263-275.
8. 1 receptor ligand. J. Nucl. Med. 1996, 37, 1203-1207.
9. 1 receptor ligand. Nucl. Med. Biol. 1997, 24, 53-59.
10. 2A receptors by PET. Appl. Radiat. Isot. 1999, 50, 887-893.
11. 2A receptor ligand. J. Nucl. Med. 2000, 41, 345-354.
12. 2A receptor in the central nervous system. Ann. Nucl. Med. 2000, 14, 247-253.
13. 2A receptors with Positron Emission Tomography. Nucl. Med. Biol. 2000, 27, 541-546.
14. 2A receptors in rats. Synapse 2001, 164-176.
15. 2A receptor system Using Positron Emission Tomography. J. Med. Chem. 2000, 43, 4359-4362.
16. 1-Adenosine receptor antagonists as ligands for positron emission tomography (PET) and single-photon emission tomography (SPET). J. Med. Chem. 1998, 41, 555-563.
17. 1-selective antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. Naunyn Schmiedebergs Arch. Pharmacol. 1987, 335, 59-63.
18. 1 adenosine receptors. Naunyn Schmiedebergs Arch. Pharmacol. 1987, 336, 204-210.
19. 1 adenosine receptors and their ligands: Overview and recent developments. Il Farm. 2001, 56, 77-80.
20. 3N HCl as combined base: Promising alternative to traditional pyridine. Tetrahedron 1999, 55, 2183-2192.
21. 18F]fluoro-2-deoxy-D-glucose: An efficient automated system for the aminopolyether supported nucleophilic fluorination. Appl Radiat. Isot. 1990, 41, 49-55.
22. 18F] fluoroheptadecanoic acid in high yields via aminopolyether supported nucleophilic fluorination. J. Labeled Cpd. Radiopharm. 1986, 23, 455-467.
23. 3 adenosine receptors expressed in the brain? Neuroreport 2000, 11, 1025-1030.
24. Rall, T. W. Drugs Used in the Treatment of Asthma. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th Ed.; Goodman, A. G., Rall, T. W., Nies, A. S., Taylor, P., Eds.; Pergamon Press: New York, 1990; Ch. 25, pp 618-637.
25. Hansch, C.; Clayton, J. M. Lipophilic character and biological activity of drugs. II. The parabolic case. J. Pharm. Sci. 1973, 62, 1-21.
26. 2 adenosine receptors. Life Sci. 1986, 39, 743-750.
27. Svennigsson, P.; Hall, H.; Sedvall, G.; Fredholm, B. B. Distribution of adenosine receptors in the postmortem human brain: An extended autoradiographic study. Synapse 1997, 27, 322-335.
28. 1 receptors and 5′-nucleotidase in the brain of some commonly used experimental animals. Neuroscience 1987, 22, 813-826.
29. Brent, D. A.; Sabatka, J. J.; Minick, D. J.; Henry, D. W. A simplified high-pressure liquid chromatography method for determining lipophilicity for structure activity relationships. J. Med. Chem. 1983, 26, 1014-1020.